GILD · News · 20261105N
Revenue Performance and Mix
GILEAD SCIENCES, INC. · 2026-11-05 · Importance 41 · Surprise 60 · In source text
Gilead reported third-quarter 2026 revenue of US$8.3 billion. The company raised its full-year product sales guidance, but the digest does not give the revised guidance amount or the quarter's year-over-year revenue change. Biktarvy was identified as a continuing driver of revenue from the HIV franchise.
Key facts
- Gilead reported third-quarter revenue of $8.30 billion, exceeding analyst estimates. source
- Gilead reported third-quarter 2026 revenue of US$8.3 billion. source
- Gilead reported third-quarter 2026 earnings of $2.55 per share. source
- Gilead's HIV franchise, led by Biktarvy, continues to drive strong revenue. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Gilead reported third-quarter revenue of $8.30 billion, exceeding analyst estimates. |